Analyst Brandon Folkes of H.C. Wainwright reiterated a Buy rating on Connect Biopharma Holdings, retaining the price target of $7.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Folkes has given his Buy rating due to a combination of factors that highlight Connect Biopharma Holdings’ promising developments and strategic decisions. The company has initiated two Phase 2 Seabreeze STAT trials to evaluate the efficacy of rademikibart in treating acute exacerbations of asthma and COPD, with results expected in the first half of 2026. The trials target a patient subgroup that has previously shown positive responses to the treatment, indicating potential success.
Additionally, Connect Biopharma has presented encouraging data from its chronic asthma studies, demonstrating significant improvements in lung function and reduced exacerbations. The company’s strategic moves, such as the submission of a new drug application by its partner Simcere in Greater China and plans for a direct Nasdaq listing, further strengthen its position. With a solid financial runway extending into 2027, Connect Biopharma is well-positioned for growth, justifying the Buy rating and a $7 price target.